Home | About IJMPO | Editorial board | Search | Ahead of print | Current Issue | Archives | Instructions | Subscribe | Advertise | Contact us |  Login 
Indian Journal of Medical and Paediatric Oncology
Search Article 
  
Advanced search 
 
Year : 2003  |  Volume : 24  |  Issue : 1  |  Page : 9-12

Waldenstrom's Macroglobulinemia : report of 8 cases


Department of Medical Oncology, IRCH-AIIMS, New Delhi

Correspondence Address:
K Ganessan
Department of Medical Oncology, IRCH-AIIMS, New Delhi

Login to access the Email id

Source of Support: None, Conflict of Interest: None


Rights and PermissionsRights and Permissions

Background: Waldenstrom's Macroglobulinemia (WM) is a lymphoproliferative disorder characterized by neoplastic B-lymphocytes infiltrating the bone marrow and other lymphoid organs with the production of monoclonal IgM protein. Patients and Methods: In this report, we review the cases of WM seen at IRCH, AIIMS, New Delhi, in the last 5 years. Criteria for diagnosis included serum monoclonal IgM protein along with 20 percent bone marrow lymphocytes. Eight cases were included in the study with a median age of 59.5 years at diagnosis and male/female ratio 7:1. Two patients were asymptomatic at diagnosis. The common clinical features at presentation were fatigue (100 percent), malaise (100 percent), bleeding tendencies (66.6 percent), symptoms suggestive of hyperviscosity (33.3 percent). Anemia was seen in 75 percent cases, hepatomegaly in 37.5 percent cases, splenomegaly in 25 percent cases, lymphadenopathy in 12.5 percent cases. None had peripheral neuropathy. Laboratory investigations revealed a mean Hb8.1g/dl, mean TLC 6.2' 10/1, mean platelet count 1.09 ' 10/1 and mean ESR 100.6 mm/hr. 75 percent cases had diffuse bone marrow involvement by lympho/lymphoplasmacytoid cells. The mean serum M spike concentration was 3.18g/dl and all the patients had IgM kappa subtype. As initial therapy, 5 patients received Chlorambucil/Prednisolone, 1 patient received VAD chemotherapy and the other 2 asymptomatic patients were observed without any therapy. None had complete response. 2 had partial response while 3 had minimal response. One of the asymptomatic case progressed after a period of 18 months of observation. 7 out of 8 cases were alive at the time last follow up. The overall median survival was 19.5 months and progression free survival was 16.3 months. Conclusion: Though a rare disorder, high clinical suspicion is required to diagnose WM. Therapy with Chlorambucil/Prednisolone provides adequate disease control.


[PDF Not available]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed712    
    Printed56    
    Emailed0    
    PDF Downloaded0    
    Comments [Add]    

Recommend this journal